All In Biotech

Investigational drug · Phase 2

YN001

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

7

Any phase or sponsor naming "YN001"

First trial start

2023

Oct 8, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "YN001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Atherosclerosis
  • Coronary Artery Disease
  • Atherosclerotic Cardiovascular Disease

Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "YN001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Atherosclerosis

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • LepodisiranLY3819469Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

  • VERVE-102LY4636581Phase 21 trial

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.